Mediclinic International PLC (LON:MDC) had its target price increased by Jefferies Group LLC from GBX 646 ($8.35) to GBX 650 ($8.40) in a research note released on Thursday morning. They currently have an underperform rating on the stock.
Several other equities research analysts also recently issued reports on MDC. Macquarie upgraded shares of Mediclinic International PLC to an outperform rating and raised their price objective for the stock from GBX 830 ($10.72) to GBX 860 ($11.11) in a research report on Friday, February 3rd. Citigroup Inc cut their price objective on shares of Mediclinic International PLC from GBX 890 ($11.50) to GBX 860 ($11.11) and set a neutral rating for the company in a research report on Wednesday, February 22nd. Credit Suisse Group AG cut their price objective on shares of Mediclinic International PLC from GBX 1,045 ($13.50) to GBX 985 ($12.73) and set an outperform rating for the company in a research report on Thursday, February 23rd. HSBC Holdings plc raised their price objective on shares of Mediclinic International PLC from GBX 640 ($8.27) to GBX 660 ($8.53) and gave the stock a reduce rating in a research report on Tuesday, April 18th. Finally, Investec restated a buy rating on shares of Mediclinic International PLC in a research report on Friday, April 28th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of GBX 850.83 ($10.99).
The firm also recently announced a dividend, which will be paid on Monday, July 31st. Stockholders of record on Thursday, June 22nd will be issued a dividend of GBX 4.70 ($0.06) per share. The ex-dividend date is Thursday, June 22nd. This is a boost from Mediclinic International PLC’s previous dividend of $3.20. This represents a dividend yield of 0.58%. About Mediclinic International PLC